|Bid||0.00 x 1300|
|Ask||30.00 x 800|
|Day's Range||19.92 - 23.90|
|52 Week Range||11.22 - 32.90|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.67|
EMERYVILLE, Calif., Dec. 17, 2018 -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to.
Orchard Therapeutics is tackling "bubble baby" disease and other rare genetic conditions with gene therapy.
Gritstone Oncology, Inc. (GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it is advancing its bispecific antibody (BiSAb) program under the direction of newly appointed vice president of Antibody Therapeutics, Jonah Rainey, Ph.D. The BiSAb program leverages the company’s artificial intelligence platform, EDGETM, for the identification and prioritization of highly tumor-specific antigens, including neoantigens, shared between patients with various solid tumors. To enable the development of BiSAb therapeutics directed to solid tumors, Gritstone has discovered antibodies with selective and high-affinity binding to tumor-specific peptide-HLA (Human Leukocyte Antigen) complexes (HLAp).
If you bought one share at the IPO price of each of the Bay Area companies who went public this year, your portfolio would be up 37 percent on the year. But you would only have a 3 percent return if you bought all of those shares at their opening market price.
Successful Initial Public Offering Raises $95.6 Million in Net Proceeds EMERYVILLE, Calif., Nov. 14, 2018 -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage.
The flood of local IPOs passed last year's total of 15 in July and appears well on its way to top the recent high 34 in 2014, with four more coming this week. Here's how the stocks from this year's crop of new Bay Area public companies have performed so far.
Gritstone Oncology Inc. has priced its initial public offering at $15 per share, at the top of a previously-set range, and will offer 6.66 million shares, more than previous plans to offer 6.07 million shares. The cancer-focused biotech company expects to begin trading on Friday on Nasdaq under the ticker "GRTS," and now expects gross proceeds of about $100 million. The offering should close on Oct. 2, the company said. Gritstone develops cancer immunotherapies, which use the body's immune system to fight cancer, and its products are specifically geared towards solid tumors. It has four products so far in extremely early development, and hopes to submit an application in the second half of this year to move one, Granite-001, into a phase 1/2 clinical trial. This year is considered a good time for biotechnology initial public offerings, with a number of buzzy companies going public in recent months. The SPDR S&P Biotech ETF has surged 13% year-to-date, compared with a 9% rise in the S&P 500 and a nearly 7% rise in the Dow Jones Industrial Average .
Gritstone Oncology Inc. sold more shares than expected at the high end of the anticipated price range of its initial public offering, raising about $100 million.
EMERYVILLE, Calif., Sept. 27, 2018-- Gritstone Oncology, Inc. today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...